# Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

> **NCT02034435** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 44 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **OTHER:** Low Salt diet plus Placebo tablet
- **OTHER:** Low Sodium diet plus Salt tablet
- **DRUG:** Epleronone
- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT02034435
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034435, "Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02034435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*